• Karen Lindsay, Ignatius Chua, Anthony Jordan, and Simone Stephens.
• Department of Clinical Immunology and Allergy, Auckland City Hospital, Auckland, New Zealand.
• Intern Med J. 2022 Dec 1; 52 (12): 212421292124-2129.

BackgroundHereditary angioedema (HAE) leads to significant morbidity and mortality from unpredictable intermittent peripheral, abdominal and laryngeal swelling. Access to appropriate healthcare and effective therapies, which can prevent and treat attacks, reduce the suffering and greatly improve quality of life. Although treatments such as C1 inhibitor (Berinert), and Icatibant are available in New Zealand (Aotearoa), there are no published data available on their use.AimTo present a national audit of HAE and acquired angioedema (AAE) in 2019.MethodsPatients were identfied and demographical and clinical data on HAE were collected retrospectively by interview and notes review.ResultsThe total number of known adult (48) and children (3) HAE and AAE (3) patients is 54. Of these, 41/54 (75%) of HAE and AAE patients were recruited to the audit. Icatibant has been available for the treatment of acute HAE attacks since 2016, and is now used in 73% of HAE patients. Icatibant is also used by patients for laryngeal attacks in the community, who may not then present to hospital. Androgens are used in half of the patients as prophylaxis, but 33% of the latter were identified as not having regular liver ultrasound screening. Tranexamic acid is used as prophylaxis in one-fifth of patients. Participants have had 40 children, half of whom may be affected. Three have been diagnosed with HAE, suggesting that the majority have not yet been tested.ConclusionsCorrective actions arising from this audit will improve our capacity to provide long-term care for HAE patients and their families.© 2021 Royal Australasian College of Physicians.

18 keywords...

hide…